Core Viewpoint - Tailin Bio (300813.SZ) reported a decline in revenue for the first three quarters of 2025, while net profit showed significant growth compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 213 million yuan, representing a year-on-year decrease of 12.08% [1] - Net profit attributable to shareholders of the listed company was 14.72 million yuan, reflecting a year-on-year increase of 30.13% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 13.05 million yuan, which is a year-on-year increase of 21.83% [1] - Basic earnings per share were 0.12 yuan [1]

Group 1 - The core viewpoint of the news is that Tailin Bio (SZ 300813) reported its third-quarter performance, showing a decline in revenue but an increase in net profit and earnings per share [1] Group 2 - For the first three quarters of 2025, the company's revenue was approximately 213 million yuan, a year-on-year decrease of 12.08% [1] - The net profit attributable to shareholders was about 14.72 million yuan, reflecting a year-on-year increase of 30.13% [1] - The basic earnings per share were 0.12 yuan, which is a year-on-year increase of 20% [1] Group 3 - As of the report, Tailin Bio's market capitalization was 3.9 billion yuan [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司 2025 年第三季度报告全文已于 2025 年 10 月 27 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅！ 证券代码：300813 证券简称：泰林生物 公告编号：2025-079 浙江泰林生物技术股份有限公司 关于 2025 年第三季度报告披露的提示性公告 特此公告。 浙江泰林生物技术股份有限公司董事会 2025 年 10 月 27 日 ...

1、审议通过《2025 年第三季度报告》 经审核，董事会认为董事会编制和审核公司 2025 年第三季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 浙江泰林生物技术股份有限公司(以下简称"公司")第四届董事会第十次会 议于 2025 年 10 月 17 日以电话、书面送达等形式发出通知，并于 2025 年 10 月 23 日在公司会议室以现场举手表决的方式召开。会议应出席董事 7 名，实际出 席董事 7 名。本次会议由叶大林先生召集和主持，公司董事会秘书及高级管理人 员列席会议。 本次会议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、 行政法规的要求，会议合法、有效。 二、董事会会议审议情况 经与会董事审议，会议通过如下议案: 证券代码：300813 证券简称：泰林生物 公告编号：2025-080 浙江泰林生物技术股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 具体内容详见公司 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥67,363,245.41, a decrease of 21.84% compared to the same period last year[5] - The net profit attributable to shareholders was ¥1,180,325.54, down 75.06% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥155,169.53, a decrease of 103.36%[5] - The company's basic earnings per share for the period was ¥0.01, down 75.00% year-on-year, while diluted earnings per share were ¥0.00, a decrease of 100.00%[5] - Total operating revenue decreased to ¥213,188,852.61 from ¥242,467,278.88, representing a decline of approximately 12.06% year-over-year[17] - Total operating costs decreased to ¥201,314,970.50 from ¥236,221,850.45, a reduction of about 14.77% year-over-year[17] - Net profit increased to ¥14,523,036.61 from ¥10,599,894.14, marking a growth of approximately 37.25% year-over-year[18] - The total comprehensive income attributable to shareholders increased to ¥14,723,274.72 from ¥11,314,672.20, an increase of about 30.67% year-over-year[18] Cash Flow - The cash flow from operating activities showed a net inflow of ¥14,859,155.99, representing a significant increase of 171.73% compared to the previous year[5] - Operating cash inflow for the current period was 255,549,763.42 CNY, up from 233,795,795.59 CNY in the previous period, representing an increase of approximately 9.4%[19] - Net cash flow from operating activities improved to 14,859,155.99 CNY from a negative 20,714,994.54 CNY in the previous period[19] - Cash inflow from investment activities totaled 763,283,824.00 CNY, compared to 569,235,804.24 CNY in the previous period, marking an increase of approximately 34%[20] - Net cash flow from investment activities was 18,597,586.88 CNY, down from 28,422,441.32 CNY in the previous period[20] - Cash flow from financing activities resulted in a net outflow of 40,384,964.10 CNY, compared to a net inflow of 4,725,027.41 CNY in the previous period[20] - The company received 11,174,000.00 CNY from financing activities, down from 15,645,426.70 CNY in the previous period[20] - Total cash outflow for operating activities was 240,690,607.43 CNY, compared to 254,510,790.13 CNY in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥934,063,765.94, a decrease of 2.69% from the end of the previous year[5] - Total current assets decreased from 632,761,878.52 CNY to 545,192,536.68 CNY, a reduction of approximately 13.78%[15] - Cash and cash equivalents decreased from 264,872,528.62 CNY to 134,971,542.57 CNY, a decline of about 49.0%[15] - Accounts receivable increased from 43,546,552.81 CNY to 49,034,637.68 CNY, an increase of approximately 12.1%[15] - Inventory increased from 144,134,014.09 CNY to 153,639,950.20 CNY, an increase of about 6.0%[15] - Total liabilities increased to ¥143,919,186.72 from ¥139,178,386.25, an increase of approximately 5.30%[16] - The equity attributable to shareholders decreased to ¥790,144,579.22 from ¥820,050,345.31, a decrease of about 3.65%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,437[11] - The largest shareholder, Ye Daling, holds 37.73% of shares, totaling 45,724,000 shares[11] - The second-largest shareholder, Ni Weiju, holds 15.18% of shares, totaling 18,402,400 shares[11] - The company has committed to a share transfer agreement with Ni Weiju, locking in 12.1 million shares for 12 months[12] Other Financial Metrics - The company reported a significant increase in intangible assets, which rose by 153.85% to ¥27,715,686.10, primarily due to land purchases[8] - The company experienced a 245.94% increase in credit impairment losses, amounting to -¥1,457,109.13, due to an increase in accounts receivable[9] - The company reported a financial expense of -¥5,896,688.66, compared to a financial expense of ¥3,361,208.48 in the previous period, reflecting a significant change in financial performance[18] - Research and development expenses remained stable at ¥49,120,227.85 compared to ¥49,454,422.64, indicating a slight decrease of 0.68%[18] - The deferred income tax liabilities decreased to ¥3,225,150.58 from ¥3,393,283.59, a reduction of approximately 4.95%[16] Audit Information - The company did not undergo an audit for the third quarter financial report[21]

Investment Rating - The report maintains a "Recommended" investment rating for the mechanical industry [6]. Core Insights - The mechanical industry is experiencing steady growth, particularly in the low-altitude economy and machinery sectors, supported by policy initiatives and technological advancements [3][4]. - The report highlights a significant increase in excavator sales, with a total of 19,858 units sold in September 2025, marking a year-on-year growth of 25.4%, including a domestic sales increase of 21.5% and an export increase of 29% [3]. Weekly Market Review - From October 13 to October 17, 2025, the Shanghai Composite Index decreased by 1.47%, while the ShenZhen Component Index and the ChiNext Index fell by 4.99% and 5.71%, respectively. The Shenwan Mechanical Equipment Index dropped by 5.84%, underperforming the CSI 300 Index by 3.62 percentage points, ranking 27th among 31 Shenwan first-level industries [11]. - Within sub-sectors, the performance varied, with general equipment down by 5.62%, specialized equipment down by 5.74%, rail transit equipment II down by 2.22%, engineering machinery down by 3.04%, and automation equipment down by 9.06% [11]. Key Sector Tracking - **Low-altitude Economy**: The Suzhou Development and Reform Commission released a dual list of capabilities and demands for the low-altitude economy, indicating strong local enterprise involvement in aircraft development and operations [3]. - **Machinery Equipment**: The report emphasizes the competitive advantage of domestic leading enterprises in both supply and demand, with a positive outlook for the engineering machinery sector [3]. Investment Recommendations - For the low-altitude economy, recommended companies include Deep City Transportation, Sujiao Science and Technology, Huasheng Group, and Nairui Radar. In the complete machine sector, focus on Wan Feng Ao Wei, Yihang Intelligent, Zongheng Co., and Green Energy Hui Charge. Key component manufacturers include Zongshen Power, Wolong Electric Drive, Yingliu Co., and Yingboer. In air traffic management and operations, consider CITIC Heli, Zhongke Xingtu, and Sichuan Jiuzhou [4]. - In the machinery equipment sector, recommended companies include Juxing Technology, Quan Feng Holdings, and Nine Company for the export chain, and Sany Heavy Industry, XCMG, and Anhui Heli for engineering machinery [4]. Economic Data Tracking - The report tracks various economic indicators, including the manufacturing PMI and fixed asset investment completion rates, which provide insights into the overall health of the manufacturing sector [40][44].

Core Viewpoint - Tailin Bio (300813) announced the acquisition of 2 patent certificates by its wholly-owned subsidiaries, Zhejiang Tailin Life Science Co., Ltd. and Zhejiang Tailin Analytical Instruments Co., Ltd. [1] Company Summary - Tailin Bio's subsidiaries have recently obtained 2 patent certificates, indicating a focus on innovation and potential growth in their product offerings [1]

每经AI快讯，泰林生物10月17日晚间发布公告称，浙江泰林生物技术股份有限公司全资子公司浙江泰 林生命科学有限公司、浙江泰林分析仪器有限公司于近期共取得了2项专利证书。专利名称分别为"微生 物检测分析仪""一种一体式两虫玻片压平装置"等。 （记者 曾健辉） 每经头条（nbdtoutiao）——"我还在！"林园硬气回应牛市亏钱，"接下来，我还会在！"坚持白酒是"快 乐需求"，科技股买了"愁得睡不着" ...

证券代码：300813 证券简称：泰林生物 公告编号：2025-078 2025 年 10 月 17 日 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林分析仪器有限公司（以 下简称"泰林分析仪器"）于近期共取得了 2 项专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 微生物检测分析仪 | 外观 | 2025300291612 | 2025/10/10 | 泰林分析仪器 | | 2 | 一种一体式两虫玻片压平装置 | 实用新型 | 2024226093270 | 2025/10/17 | 泰林生命科学 | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林分析仪器近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林分析仪 器进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制， 保持技术领先地位，提升核心竞争力。 特此公告。 浙江泰林生物技术股份有限公 ...

每经AI快讯，10月16日，泰林生物（300813）公告，青岛高得投资合伙企业(有限合伙)作为控股股东、 实际控制人的一致行动人，计划自2025年7月16日起15个交易日后的3个月内，通过集中竞价、大宗交易 等方式减持不超过181.95万股，占公司总股本的1.50%。截至2025年10月15日，高得投资实际减持 181.18万股，占公司总股本的1.49%，减持计划已完成。减持后，高得投资持有546.63万股，占公司总 股本的4.51%。 ...